Revenue: As of FY2025 Q3, the actual value is USD 8.659 M, beating the estimate of USD 7.92 M.EPS: As of FY2025 Q3, the actual value is USD -0.55, beating the estimate of USD -0.584.EBIT: As of FY2025 Q3, the actual value is USD -25.05 M.<h3>Segment Revenue</h3><ul><li>Collaboration Revenue: For the three months ended September 30, 2025, collaboration revenue was $8.7 million, a decrease from $11.5 million in the same period in 2024. For the nine months ended September 30, 2025, collaboration revenue was $21.3 million, down from $42.7 million in the same period in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: The net loss for the three months ended September 30, 2025, was - $20.4 million, compared to - $18.8 million in the same period in 2024. For the nine months ended September 30, 2025, the net loss was - $65.3 million, compared to - $54.7 million in the same period in 2024.</li><li>Research and Development Expenses: For the three months ended September 30, 2025, R&amp;D expenses were $25.3 million, a decrease from $26.3 million in the same period in 2024. For the nine months ended September 30, 2025, R&amp;D expenses were $72.9 million, down from $86.0 million in the same period in 2024.</li><li>General and Administrative Expenses: For the three months ended September 30, 2025, G&amp;A expenses were $6.2 million, a decrease from $7.6 million in the same period in 2024. For the nine months ended September 30, 2025, G&amp;A expenses were $20.0 million, down from $24.9 million in the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: For the nine months ended September 30, 2025, net cash used in operating activities was - $65.3 million, compared to - $82.8 million in the same period in 2024.</li><li>Net Cash Provided by Investing Activities: For the nine months ended September 30, 2025, net cash provided by investing activities was $71.2 million, compared to net cash used of - $116.7 million in the same period in 2024.</li><li>Net Cash Used in Financing Activities: For the nine months ended September 30, 2025, net cash used in financing activities was - $0.4 million, compared to net cash provided of $84.0 million in the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: Metagenomi, Inc. plans to advance its MGX-001 program into clinical development, with pre-IND regulatory meetings by the end of 2025, and aims to submit IND and CTA submissions in the fourth quarter of 2026, with clinical trials initiation in 2027. The company is also focusing on leveraging its MGX-001 site-specific genome integration approach to target secreted protein deficiencies and plans to demonstrate NHP proof-of-concept for its lead target in 2025.</li><li>Non-Core Business: The company is exploring opportunities to pursue neuromuscular and liver disease targets, such as A1AT and Wilson Disease, and is considering partnerships including cell therapy applications.</li><li>Priority: The company emphasizes its collaboration with Ionis Pharmaceuticals, Inc., planning to nominate a development candidate from the Wave 1 targets in 2025 and initiate IND-enabling activities in 2026.</li></ul>

Metagenomi | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 8.659 M